Anebulo Pharmaceuticals, Inc. (ANEB) stock
ANEBNasdaqPharmaceutical PreparationsFiscal year ends June 30
$0.00+0.00 (+75.00%)
Close on Oct 19, 2026Market cap $28.76KP/E –Yield –
Anebulo Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Anebulo Pharmaceuticals's R&D Expenses for the twelve months ending Dec 31, 2025 was $3.74M, down 0.3% year over year. For fiscal 2025 it was $4.30M, up 21.2% from the year before. The highest annual figure on record is $5.60M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $4.30M | +21.2% |
| FY2024 | Jun 30, 2024 | $3.55M | -36.6% |
| FY2023 | Jun 30, 2023 | $5.60M | +89.1% |
| FY2022 | Jun 30, 2022 | $2.96M | +30.5% |
| FY2021 | Jun 30, 2021 | $2.27M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $1.16M | -4.6% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $809.99K | -38.4% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $1.13M | +140.8% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $638.32K | -14.7% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $1.22M | +14.9% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $1.31M | +3.5% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $467.71K | -67.0% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $748.34K | -31.3% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $1.06M | -43.2% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $1.27M | +3.8% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $1.42M | +26.7% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $1.09M | +19.0% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $1.87M | +778.2% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $1.22M | +71.1% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $1.12M | -38.1% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $915.36K | +235.3% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $212.94K | +25.3% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $715.10K | +3425.1% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $1.81M | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $273.04K | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $169.98K | – |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $20.29K | – |
See a number that looks wrong?